Caño-Velasco J, Herranz-Amo F, Barbas-Bernardos G, Polanco-Pujol L, Lledó-García E, Hernández-Fernández C
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.
Actas Urol Esp (Engl Ed). 2019 Jan-Feb;43(1):18-25. doi: 10.1016/j.acuro.2018.07.002. Epub 2018 Aug 14.
The onset of second primary tumours should be considered in high-risk prostate cancer patients in the natural course of the disease. Our aim was to evaluate the influence of primary treatment with curative intent for these patients on the development of second primary tumours.
A retrospective study of 286 patients diagnosed between 1996 and 2008, treated by radical prostatectomy (n=145) or radiotherapy and androgen blockade (n=141). The homogeneity of both series was analysed using the Chi-squared test for the qualitative variables, and the Student's t-test for the quantitative variables. A multivariate Cox regression analysis was performed to assess whether the type of primary treatment influenced the development of second tumours.
The median age was 66 years, and the median follow-up was 117.5 months. At the end of follow-up, 60 patients (21%) had developed a second primary tumour. In the prostatectomy group it was located in the pelvis in 13 (9%) cases, and those treated with radiotherapy and hormonotherapy in 8 (5.7%) cases (P=.29). The most common organ sites were: colo-rectal in 17 (28.3%) patients, the lung in 11 (18.3%), and the bladder in 6 (10%) patients. In the multivariable analysis, the risk of a second tumour doubled for those treated with radiotherapy and hormonotherapy (HR=2.41, 95%CI: 1.31-4.34, P=.005) compared to the patients treated by prostatectomy. Age and rescue radiotherapy did not behave as independent predictive factors.
The onset of a second primary tumour was related with the primary treatment given; thus the risk for those treated with radiotherapy and androgen deprivation therapy more than doubled.
在高危前列腺癌患者疾病的自然进程中,应考虑第二原发性肿瘤的发生。我们的目的是评估对这些患者进行根治性治疗对第二原发性肿瘤发生的影响。
对1996年至2008年间诊断的286例患者进行回顾性研究,这些患者接受了根治性前列腺切除术(n = 145)或放疗及雄激素阻断治疗(n = 141)。使用卡方检验分析定性变量的两个系列的同质性,使用学生t检验分析定量变量的同质性。进行多变量Cox回归分析以评估原发性治疗类型是否影响第二肿瘤的发生。
中位年龄为66岁,中位随访时间为117.5个月。随访结束时,60例患者(21%)发生了第二原发性肿瘤。在前列腺切除术组中,13例(9%)位于盆腔,接受放疗和激素治疗的患者中有8例(5.7%)(P = 0.29)。最常见的器官部位是:17例(28.3%)患者为结肠直肠,11例(18.3%)为肺,6例(10%)为膀胱。在多变量分析中,与接受前列腺切除术的患者相比,接受放疗和激素治疗的患者发生第二肿瘤的风险增加了一倍(HR = 2.41,95%CI:1.31 - 4.34,P = 0.005)。年龄和挽救性放疗不作为独立的预测因素。
第二原发性肿瘤的发生与所给予的原发性治疗有关;因此,接受放疗和雄激素剥夺治疗的患者的风险增加了一倍多。